Specific Immunotherapy (SIT)

Sunday, 4 December 2011

Sunday | top

08:00 - 09:30

New Horizons Session 1: Specific Immunotherapy (SIT): History, Mechanisms and Future - This session is co-sponsored by ALK-Abello & MSD
Gran Cancún (Cancún Center)
 Chairpersons: Richard F. Lockey (US) and Dermot Ryan (United Kingdom)
08:00 - 08:10
Welcoming Remarks
08:10 - 08:30
1-1NH: History of SIT
08:30 - 08:50
1-2NH: Mechanisms of Sub-Cutaneous Immunotherapy (SCIT) | Stephen Durham (United Kingdom)
08:50 - 09:10
1-3NH: Mechanisms of Sub-Lingual Immunotherapy (SLIT) | Jean-Pierre Allam (Germany)
09:10 - 09:30
1-4NH: Newer Forms of SIT | Rudolf Valenta (Austria)

10:00 - 11:45

New Horizons Session 1: Specific Immunotherapy (SIT): Which Patients for SIT and Anti-IgE? - This session is co-sponsored by ALK-Abello & MSD
Gran Cancún (Cancún Center)
 Chairpersons: Richard F. Lockey (US) and Barbara Rogala (Poland)
10:00 - 10:05
Welcoming Remarks
10:05 - 10:30
1-5NH: For SCIT? | Harold Nelson (US)
10:30 - 10:55
1-6NH: For SLIT? | Giorgio Walter Canonica (Italy)
10:55 - 11:20
1-7NH: For Anti-IgE? | Daniel Jackson (US)
11:20 - 11:35
1-8NH: Presentation of the WAO Henning Løwenstein Research Award to Zoulfia Allakhverdi (Canada) and Natalija Novak (Germany)
11:35 - 11:45
Discussion

13:00 - 14:30

New Horizons Session 1: Specific Immunotherapy (SIT): Effectiveness of SIT - This session is co-sponsored by ALK-Abello & MSD
Gran Cancún (Cancún Center)
 Chairpersons: Eliana Risquez (Venezuela) , Anthony Frew (United Kingdom) and Carlo Tomino (Italy)
13:00 - 13:05
Welcoming Remarks
13:05 - 13:30
1-9NH: SLIT | Giovanni Passalacqua (Italy)
13:30 - 13:55
1-10NH: SIT and Children | Erkka Valovirta (Finland)
13:55 - 14:20
1-11NH: SIT and Asthma | Moises Calderon
14:20 - 14:30
Discussion

15:00 - 16:30

New Horizons Session 1: Specific Immunotherapy (SIT): Practical Considerations for SIT - This session is co-sponsored by ALK-Abello & MSD
Gran Cancún (Cancún Center)
 Chairpersons: John Kelso (US) and Désirée Larenas Linnemann (Mexico)
15:00 - 15:05
Welcoming Remarks
15:05 - 15:30
1-12NH: When Should SIT be Started and Why? | Lars Jacobsen (Denmark)
15:30 - 15:55
1-13NH: Adverse Effects | Linda Cox (US)
15:55 - 16:20
1-14NH: Cost Effectiveness and Compliance | Cheryl Hankin (US)
16:20 - 16:30
Discussion